On September 25, i-mab announced that it has reached a strategic cooperation with Sanofi on the development, production, and commercialization of its independently developed global innovative CD73 antibody ulileimab in the greater China region. Sanofi will pay i-mab approximately 32 million euros as an upfront payment and near-term milestone payments, as well as certain registration and sales milestone payments; with a potential total consideration not exceeding 0.213 billion euros. (Yicai)
天境生物与赛诺菲达成授权协议，潜在总价最高达2亿欧元
I-mab and Sanofi have reached an authorization agreement, with a potential total price of up to 0.2 billion euros.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated